SynthesisAdvances in nutrition (Bethesda, Md.)2026
Study Design Complexity and Participant Completion in Dietary Trials for Inflammatory Bowel Disease: A Systematic Review and Metaresearch Study.
Synthesis in Advances in nutrition (Bethesda, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Completion Rates of Food Frequency Questionnaires and Food Records in People with Chronic Conditions: Systematic Review and Meta-Analysis.Nutrients · 2026Pooled it
- Rethinking Restrictive Diets in IBD: Toward an Inclusion-Focused Nutritional Paradigm.Current gastroenterology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dietary intervention trials in inflammatory bowel disease (IBD) are difficult to implement due to poor adherence, despite their increasing importance for disease management. We conducted a systematic review to evaluate completion rates of dietary intervention trials recruiting patients with IBD and assess completion rate associations with trial design features. We systematically searched MEDLINE (Ovid), Embase (Ovid) and CINAHL (EBSCO) databases on 13 May, 2024 for randomized controlled trials examining dietary or macronutrient supplementary intake effects in patients with IBD, excluding enteral and parenteral nutrition trials. The flow of participants and prespecified trial design features were extracted. Completion rates by study arm were estimated using a multilevel mixed-effects model. Covariates were assessed via metaregression and presented as a forest plot. For each study, the risk of bias was assessed using the Cochrane Collaboration appraisal tool (RoB2) for randomized trials and randomized cross-over trials. Three main risk of bias (RoB) domains (selection and detection biases) were associated with the completion rate. These were included to explore potential biases in the reported information. In total, 62 trials comprising 122 study arms and 3523 participants were included. The overall pooled completion rate was 0.84 [95% confidence interval (CI): 0.80, 0.87] with lower rates of completion in trials published within the last 10 y. Low completion rates were associated with fecal sampling (0.75, 95% CI: 0.50, 1.00), study duration of 4-8 wk (0.79, 95% CI: 0.40, 1.00), and having a low RoB in the management of missing data (0.74, 95% CI: 0.34, 1.00). Overall, the completion rates of patients with IBD participating in controlled dietary intervention trials was high, and there was <15% variation in completion rates in relation to trial design. No linear correlation with trial duration was found. The most pronounced association with low completion was a comprehensive intervention content, i.e., fecal sampling. This study was registered at PROSPERO CRD42022327783.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.